Interferon Alfacon-1 Articles
Three Rivers gets expanded rights to Infergen
22 September 2008
Three Rivers finalizes acquisition of Infergen from Valeant
21 January 2008
Valeant slumps into 3rd-qtr $12M loss
12 November 2007
Stock Commentary - New York week to Nov 5, 2007
12 November 2007
Valeant's 2nd-qtr 2007 income stays constant
13 August 2007
Stock Commentary - New York week to May 7, 2007
14 May 2007
Valeant reports strong 48-week data for Infergen
6 November 2006
Valeant 1st-qtr 2006 loss deepens to $6.4M
15 May 2006
Stock Commentary - New York week to Dec 5
12 December 2005
Valeant to buy Infergen from InterMune
5 December 2005
InterMune posts 2004 results
21 February 2005
InterMune posts 2004 results
21 February 2005
Japan stock market three weeks to January 3
10 January 2005
InterMune cuts 3rd-qtr 2004 loss 63%
8 November 2004
InterMune's net loss falls 36% for 2nd-qtr
9 August 2004
InterMune losses tumble 38%
10 May 2004
InterMune unveils its path for the future
12 April 2004
Infergen outdoes Rebetron in Phase IV study
15 November 2001
Japan pharma stocks: week to August 13
14 August 2001
InterMune forecasts larger losses
18 June 2001
Yamanouchi watching Lipitor developments
24 November 1999
Latest Wave Of US 1st Quarter Results
29 October 1998
Maxim And BioNative's RCC Collaboration
21 September 1998
US Quarterly Financial Results Round-Up
23 April 1998
60% Success Rate With Infergen In Hep C
16 April 1998
Maxim Progresses With Maxamine Trials
26 February 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
1997: Another Good Year For New Chemical Entities
6 January 1998
US 3rd Qtr Corporate Results Round-Up
30 October 1997
Amgen's Infergen Approved; 1st New Product In 6 Years
9 October 1997
Biogen Sues Amgen Over Infergen
7 August 1997
Outlook Favorable For Global Health Care
23 June 1997
EPS Rises 27% At Amgen In 1st Qtr
22 April 1997
S-P Sues Amgen Over Infergen
9 December 1996
Amgen Licence CIFN Rights To Yamanouchi
24 June 1996
Amgen Entering New Product Cycle
1 April 1996
Strong International Sales For US Cos In 2nd Qtr
31 July 1995
Showing 1-44 of 44 articles
- 1
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
